Get started
Marksans Pharma LimitedMarksans Pharma LimitedMarksans Pharma Limited

Marksans Pharma Limited

No trades
No trades
OverviewFinancialsDocumentsNewsCommunityTechnicalsForecastsSeasonalsETFs
Full chart
Full chart

Compare with Marksans Pharma Limited



Key stats


Market capitalization
‪150.90 B‬ INR
Dividend yield (indicated)
0.27%
Price to earnings Ratio (TTM)
29.20
Basic EPS (TTM)
11.40 INR
Net income (FY)
‪4.18 B‬ INR
Revenue (FY)
‪29.46 B‬ INR
Shares float
‪214.46 M‬
Beta (1Y)
0.94

Latest earnings


Last report date
Aug 12, 2026
Report period
Q1 2026
EPS
3.45 INR
Revenue
‪8.41 B‬ INR
Earnings call summary

Q1 FY26 saw 5% revenue growth and gross margin expansion, but profitability was impacted by one-time costs and UK price erosion. US business grew 30% year-on-year, while UK and Australia faced seasonal and pricing headwinds. Outlook remains cautious amid tariff uncertainties.

Employees


Employees (FY)
‪1.69 K‬
Change (1Y)
+336+24.91%
Revenue / Employee (1Y)
‪17.48 M‬ INR
Net income / Employee (1Y)
‪2.48 M‬ INR

Company info


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Mark Bosco Saldanha
Website
marksanspharma.com
Headquarters
Mumbai
Founded
1992
IPO date
Apr 3, 2002
ISIN
INE750C01026
FIGI
BBG000D7VQM3
Identifiers
ISIN INE750C01026
CFI code
ESVUFN
Marksans Pharma Ltd. engages in the research, manufacture, marketing, and sale of pharmaceutical formulations. Its product portfolio includes tablets, hard capsules, soft gelatin capsules, oral liquids, and ointments. It operates through the following geographical segments: US and North America, Europe and UK, Australia and New Zealand, India, and Rest of World. The company was founded by Mark Bosco Saldanha on April 16, 1992 and is headquartered in Mumbai, India.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ETFs holding the stock


SPEM
State Street SPDR Portfolio Emerging Markets ETF
Weight0.06%
Market value‪11.57 M‬
SMIN
Ishares MSCI India Small Cap ETF
Weight0.20%
Market value‪1.51 M‬
EPI
WisdomTree India Earnings Fund
Weight0.05%
Market value‪768.99 K‬
EWX
State Street SPDR S&P Emerging Markets Small Cap ETF
Weight0.07%
Market value‪493.32 K‬
GMF
State Street SPDR S&P Emerging Asia Pacific ETF
Weight0.10%
Market value‪448.60 K‬
AVES
Avantis Emerging Markets Value ETF
Weight0.02%
Market value‪289.82 K‬
SPYX
State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF Accum USD
Weight0.03%
Market value‪179.98 K‬
EEMS
iShares MSCI Emerging Markets Small Cap ETF
Weight0.05%
Market value‪176.32 K‬
EUNI
iShares MSCI EM Small Cap UCITS ETF
Weight0.05%
Market value‪157.61 K‬
AVEE
Avantis Emerging Markets Small Cap Equity ETF
Weight0.04%
Market value‪48.45 K‬
MOHEALTH
Motilal Oswal S&P BSE Healthcare ETF
Weight0.34%
Market value‪15.79 K‬

Explore more ETFs 

Frequently asked questions


The current price of MARKSANS is 326.50 INR — it has decreased by −0.47% in the past 24 hours. Watch Marksans Pharma Limited stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NSE exchange Marksans Pharma Limited stocks are traded under the ticker MARKSANS.
MARKSANS stock has risen by 21.03% compared to the previous week, the month change is a 20.66% rise, over the last year Marksans Pharma Limited has showed a 81.39% increase.
We've gathered analysts' opinions on Marksans Pharma Limited future price: according to them, MARKSANS price has a max estimate of 385.00 INR and a min estimate of 378.00 INR. Watch MARKSANS chart and read a more detailed Marksans Pharma Limited stock forecast: see what analysts think of Marksans Pharma Limited and suggest that you do with its stocks.
MARKSANS reached its all-time high on Dec 2, 2024 with the price of 358.70 INR, and its all-time low was 0.85 INR and was reached on May 28, 2003. View more price dynamics on MARKSANS chart.
See other stocks reaching their highest and lowest prices.
MARKSANS stock is 3.43% volatile and has beta coefficient of 0.94. Track Marksans Pharma Limited stock price on the chart and check out the list of the most volatile stocks — is Marksans Pharma Limited there?
Today Marksans Pharma Limited has the market capitalization of ‪150.29 B‬, it has increased by 6.60% over the last week.
Yes, you can track Marksans Pharma Limited financials in yearly and quarterly reports right on TradingView.
Marksans Pharma Limited is going to release the next earnings report on Nov 5, 2026. Keep track of upcoming events with our Earnings Calendar.
MARKSANS net income for the last quarter is ‪1.57 B‬ INR, while the quarter before that showed ‪1.48 B‬ INR of net income which accounts for 0.00% change. Track more Marksans Pharma Limited financial stats to get the full picture.
Yes, MARKSANS dividends are paid annually. The last dividend per share was 0.80 INR. As of today, Dividend Yield (TTM)% is 0.24%. Tracking Marksans Pharma Limited dividends might help you take more informed decisions.
Marksans Pharma Limited dividend yield was 0.57% in 2025, and payout ratio reached 9.76%. The year before the numbers were 0.36% and 9.53% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Aug 19, 2026, the company has ‪1.69 K‬ employees. See our rating of the largest employees — is Marksans Pharma Limited on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Marksans Pharma Limited EBITDA is ‪7.14 B‬ INR, and current EBITDA margin is 20.36%. See more stats in Marksans Pharma Limited financial statements.
Like other stocks, MARKSANS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Marksans Pharma Limited stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Marksans Pharma Limited technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Marksans Pharma Limited stock shows the strong buy signal. See more of Marksans Pharma Limited technicals for a more comprehensive analysis.